

Title (en)  
SUPPRESSION OF CARTILAGE DEGRADATION VIA THE ESTROGEN RECEPTOR

Title (de)  
BEKÄMPFUNG DES KNORPELGEWEBEABBAUS DURCH WIRKUNG AUF DAS ÖSTROGENREZEPTOR

Title (fr)  
SUPPRESSION DE LA DEGRADATION DU CARTILAGE A L'AIDE DU RECEPTEUR DES OESTROGENES

Publication  
**EP 1465619 A1 20041013 (EN)**

Application  
**EP 03702427 A 20030113**

Priority  
• EP 0300241 W 20030113  
• GB 0200743 A 20020114  
• GB 0209495 A 20020425  
• US 34873002 P 20020114

Abstract (en)  
[origin: WO03063859A1] The present invention relates to the pharmaceutical use of selective estrogen receptor modulators (SERMs) alone or in combination with progestins for the treatment or prevention of diseases associated with elevated cartilage degradation. In particular this invention relates to the pharmaceutical use of chroman derivatives in combination with moretindrone for the treatment or prevention of osteoarthritis or rheumatoid arthritis.  
[origin: WO03063859A1] The present invention relates to the pharmaceutical use of selective estrogen receptor modulators SERMs alone or in combination with progestins for the treatment or prevention of diseases associated with elevated cartilage degradation. In particular this invention relates to the pharmaceutical use of chroman derivatives in combination with moretindrone for the treatment or prevention of osteoarthritis or rheumatoid arthritis.

IPC 1-7  
**A61K 31/353**; **A61K 31/37**; **A61K 31/138**; **A61K 31/4535**; **A61P 19/02**; **A61P 19/10**

IPC 8 full level  
**C07D 405/12** (2006.01); **A61K 31/138** (2006.01); **A61K 31/353** (2006.01); **A61K 31/37** (2006.01); **A61K 31/40** (2006.01); **A61K 31/4535** (2006.01); **A61K 31/567** (2006.01); **A61K 31/568** (2006.01); **A61K 31/57** (2006.01); **A61K 31/573** (2006.01); **A61P 3/04** (2006.01); **A61P 5/00** (2006.01); **A61P 9/00** (2006.01); **A61P 13/02** (2006.01); **A61P 15/00** (2006.01); **A61P 17/14** (2006.01); **A61P 19/02** (2006.01); **A61P 19/10** (2006.01); **A61P 25/00** (2006.01); **A61P 27/12** (2006.01); **A61P 29/00** (2006.01); **A61P 35/00** (2006.01); **C07J 5/00** (2006.01); **C07J 7/00** (2006.01)

CPC (source: EP)  
**A61K 31/138** (2013.01); **A61K 31/353** (2013.01); **A61K 31/37** (2013.01); **A61K 31/4535** (2013.01); **A61K 31/57** (2013.01); **A61P 3/04** (2017.12); **A61P 5/00** (2017.12); **A61P 9/00** (2017.12); **A61P 13/02** (2017.12); **A61P 15/00** (2017.12); **A61P 17/14** (2017.12); **A61P 19/02** (2017.12); **A61P 19/10** (2017.12); **A61P 25/00** (2017.12); **A61P 27/12** (2017.12); **A61P 29/00** (2017.12); **A61P 35/00** (2017.12)

Citation (search report)  
See references of WO 03063859A1

Designated contracting state (EPC)  
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR

DOCDB simple family (publication)  
**WO 03063859 A1 20030807**; EP 1465619 A1 20041013; JP 2005524630 A 20050818

DOCDB simple family (application)  
**EP 0300241 W 20030113**; EP 03702427 A 20030113; JP 2003563549 A 20030113